Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with Medicare ...

Entresto is a brand-name prescription medication containing sacubitril and valsartan. The FDA approved generic versions of Entresto in May 2024, and the drug was launched in July 2025. According to ...

By Bhanvi Satija and Marleen Kaesebier LONDON, April 28 (Reuters) - Novartis posted first-quarter core operating profit and revenues below market expectations on Tuesday, hit by a slump in sales of ...

As blockbuster heart failure drug Entresto inches toward a patent cliff, Novartis is calling on the FDA—again—to keep early-bird generics at bay. At the time, Novartis argued greenlighting any generic ...

Update 3:48pm: Adds Novartis comment on appeal, updates shares. Novartis (NYSE:NVS) lost a patent ruling related to its blockbuster heart failure drug Entresto. Novartis ADRs fell 3.4%. A court found ...

Novartis is already suing a long list of generics producers that aim to bring copycats of the company's popular heart failure drug Entresto to market. Now, the Swiss pharma itself has become target in ...

Generic competition for Promacta, a blood disorder drug, and Tasigna, a leukemia treatment, is adding pressure on ​Novartis ...

Novartis was unsuccessful in convincing a federal court to block MSN Pharmaceuticals from introducing its own version of Novartis' heart-failure drug Entresto, according to a court decision issued on ...

The Federal Circuit recently reversed a District of Delaware decision that invalidated claims of Novartis’s Orange Book listed patent, U.S. Patent No. 8,101,659 (the “’659 patent”), for its ...

By Bhanvi Satija and Marleen Kaesebier LONDON, April 28 (Reuters) - Novartis posted first-quarter core operating profit and ...